

# Global clinical development pipeline

As of: 05 Aug 2025

Phase 1

SonrotoclaxBCL2i

● 101 B-cell malignancies  
● 102 B-cell malignancies  
● 103 AML/MDS  
● 105 R/R MM t(11;14)  
● 108 Dose ramp-up

BGB-16673BTK CDAC

● 101 B-cell malignancies  
● 102 B-cell malignancies  
● 104 B-cell malignancies  
● 107 Chronic spontaneous urticaria

BGB-21447BCL2i

● 101 B-cell malignancies  
● 102 Metastatic breast cancer

BGB-43395CDK4i

● 101/102 Solid tumors

BG-C9074<sup>1</sup>B7-H4 ADC

● 101 Solid tumors

BG-68501<sup>2</sup>CDK2i

● 101 Solid tumors

BGB-A3055CCR8 mAb

● 101 Solid tumors

BGB-B455CLDN 6 x CD3 BsAb

● 101 Solid tumors

BG-58067MTA Coop. PRMT5i

● 101 Solid tumors

BG-89894<sup>3</sup>MAT2Ai

● 101 Solid tumors

BG-C354B7-H3 ADC

● 101 Solid tumors

Phase 2

ZanubrutinibBTKi

● 215 B-cell malignancies

SonrotoclaxBCL2i

● 203 R/R WM  
● 204 TN CLL/SLL

BGB-16673BTK CDAC

● 101 R/R CLL & R/R WM  
● 102 R/R CLL

Blinatumomab<sup>4</sup>CD19 x CD3 BiTE®

● 20190359 R/R BP-ALL

Tarlatamab<sup>4</sup>DLL3 x CD3 BiTE®

● 20240092 2L+ SCLC (Alt dosing)

BGB-45035IRAK4 CDAC

● 201 Rheumatoid Arthritis\*\*

Phase 3

ZanubrutinibBTKi

● 306 TN MCL  
● 308 R/R MZL, R/R FL  
● 309 pMN

SonrotoclaxBCL2i

● 301 TN CLL  
● 302 R/R MCL  
● 303 R/R CLL/SLL

BGB-16673BTK CDAC

● 302 R/R CLL  
● 303 R/R CLL/SLL  
● 304 R/R CLL/SLL (vs. Pirto)\*\*

PamiparibPARPi

● 302 2L PSOC

Tarlatamab<sup>4</sup>DLL3 x CD3 BiTE®

● 20200041 1L ES-SCLC (+Durva Maint.)  
● 20240178 1L ES-SCLC (+Durva +Chemo Induction; +Durva Maint)\*\*  
● 20230016 LS-SCLC

Zanidatamab<sup>5</sup>HER2 BsAb

● 301 1L HER2+ GEA

TislelizumabPD-1 mAb

● 314 R/R cHL  
● 310 1L UBC  
● 316 SubQ\*\*

Accepted Submissions  
*Major markets*

ZanubrutinibBTKi

● 114 Tablet formulation (EU)

SonrotoclaxBCL2i

● 201 R/R MCL (CN)  
● 202 R/R CLL (CN)

Tarlatamab<sup>4</sup>DLL3 x CD3 BiTE®

● 20230273 3L+ SCLC (CN)  
● 20210004 2L SCLC (CN)

TislelizumabPD-1 mAb

● 315 Neo/adj NSCLC (EU)  
● Alternate dosing Q6W (US, CN, EU)

● Heme ● Breast / Gyn ● Other Cancers

● Lung ● GI ● I&I

Accepted submissions shown for major markets US, CN, EU, JP

1) DualityBio collaboration, 2) Ensem collaboration, 3) CSPC collaboration, 4) Amgen collaboration, 5) Zymeworks/Jazz collaboration.

Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

\*\* Trial is listed on [clinicaltrials.gov](https://clinicaltrials.gov), but may not have subjects enrolled

